RosTrace

Tag: PrecisionMedicine

Robin Hayes

Genetic Variations in Prader-Willi Syndrome Illuminate Links to Autism and Psychosis

Prader-Willi syndrome (PWS) is a rare genetic disorder occurring in approximately 1 in 16,000 to 1 in 76,000 births across all ethnicities and genders. Characterized by hypotonia, hyperphagia and distinct craniofacial features, PWS has also emerged as a valuable model for studying neurodevelopmental and psychiatric conditions. In a newly published Invited Expert Review in Genomic Press, researchers from the University of Haifa synthesize cutting-edge findings that reveal how PWS’s genetic subtypes correlate with divergent psychiatric outcomes—namely autism spectrum disorder (ASD) and psychotic spectrum disorders (PSD). These insights hold promise for unraveling the genetic architecture of neuropsychiatric vulnerability and advancing precision psychiatry.

· 5 min read

Ash Cooper

MicroRNA Revolution: Tiny Molecules, Big Impact on Diagnostics and Precision Medicine

When the first microRNAs (miRNAs) were linked to gene‑silencing more than two decades ago, few foresaw how profoundly these 20–25‑nucleotide regulators would transform life science. Today, miRNAs inform everything from basic cell‑biology experiments to multi‑site clinical trials and point‑of‑care diagnostic devices. In an exclusive interview with News‑Medical, Dr. Lohit Khera—Head of Scientific Sales at Canadian biotech firm Norgen Biotek—explains how advances in RNA extraction, automation, and artificial intelligence (AI) are accelerating the move from discovery to routine clinical deployment.

· 6 min read

Ash Cooper

Breakthrough in Mitochondrial Medicine: Scientists Develop Tool for Precise mtDNA Editing

In a landmark study that could redefine the landscape of mitochondrial disease research and treatment, scientists in Japan have developed a groundbreaking tool capable of precisely editing mitochondrial DNA (mtDNA) in human cells. The innovation holds promise for both deeper understanding and therapeutic management of devastating conditions like MELAS syndrome and mitochondrial diabetes.

· 4 min read

Ash Cooper

Optimizing mRNA Transfection in T-Cells: Sartorius Leverages High-Throughput Cytometry to Enhance Cancer Immunotherapy Outcomes

A new study sponsored by Sartorius, a global leader in biopharmaceutical innovation, has demonstrated promising advancements in optimizing mRNA transfection in human T-cells using high-throughput cytometry and live-cell imaging. By utilizing jetMESSENGER®, a non-viral mRNA transfection reagent, and leveraging state-of-the-art platforms like the Incucyte® Live-Cell Analysis System and iQue® High-Throughput Screening cytometer, Sartorius researchers have identified enhanced workflows that preserve T-cell viability, improve transfection efficiency, and amplify cytotoxic activity against cancer cells.

· 4 min read

Robin Hayes

New Biomarker Predicts Multiple Sclerosis Progression, Offering Hope for Better Treatment Strategies

Researchers at the University of Turku have identified a novel biomarker that may revolutionize how clinicians assess the progression and severity of multiple sclerosis (MS), a chronic autoimmune disease of the central nervous system. The groundbreaking study, published in Nature Medicine, offers promising new directions for both targeted treatment and faster development of therapeutic drugs—particularly for progressive MS, which remains one of the most challenging forms of the disease to treat.

· 3 min read

Ash Cooper

Tailored Biopsies Significantly Improve Patient Outcomes, ROME Trial Finds

CHICAGO – A groundbreaking clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 has demonstrated that patients with advanced solid tumors experience significantly improved survival outcomes when treatment is tailored using information from both tissue and liquid biopsies. The findings from the phase II, multicenter ROME trial could redefine the approach to precision oncology and patient care.

· 5 min read

Robin Hayes

MD Anderson Trials Show Breakthrough Results at AACR Annual Meeting 2025

At the prestigious American Association for Cancer Research (AACR) Annual Meeting 2025, researchers from The University of Texas MD Anderson Cancer Center unveiled promising results from several pioneering clinical trials that could redefine treatment paradigms across multiple cancer types. The presentations, covering personalized vaccines, metastasis-directed radiation therapy, and engineered exosome therapeutics, signal major advances in personalized oncology and immunotherapy.

· 3 min read